Globus Medical
GMED NYSE· Health Care Equipment
Last close · Oct 26, 2026
$81.83
KIRA · Stoqly’s AI analyst, in plain words
- Globus Medical had $2.9B of revenue in fiscal 2025, up 16.7% on the year before. Over five years, revenue changed +30.1% a year on average.
- Its operating margin was 16.3%, up 9.7 pts: of every 100 in sales, about 16 is left after running the business.
- Globus Medical made $538M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 15.4% a year.
- Free cash flow was $589M in fiscal 2025, 20.0% of revenue.
- Globus Medical returned $300M to shareholders in fiscal 2025, 51% of free cash flow. The diluted share count fell 0.6%.
- Globus Medical has $556M more cash than debt.
Market cap
$11.2B
P/E
21.0x
Revenue
$2.9B
Net income
$538M
Free cash flow
$589M
Operating margin
16.3%
Globus Medical in 30 seconds · fiscal 2025
Are sales growing?
+16.7%
Yes. Sales grew 16.7% last year.
Does it make a profit?
18.3%
Yes. It keeps 18.3% of every sale as profit.
Does profit turn into cash?
20.0%
Yes. 20.0% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
9 / 9
Solid. It passes 9 of 9 health tests.
How is the share priced?
21.0x
One share costs 21.0 times its yearly profit per share. Typical for its sector: 28.4x.
What Globus Medical does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- GLOBUS MEDICAL, INC.
- CIK
- 0001237831
Globus Medical · GMED
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $958M | $1.0B | $1.6B | $2.5B | $2.9B |
| Revenue growth | 21.4% | 6.8% | 53.3% | 60.6% | 16.7% |
| Gross margin | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% |
| Operating margin | 18.0% | 22.3% | 8.5% | 6.6% | 16.3% |
| Net income | $149M | $190M | $123M | $103M | $538M |
| Net margin | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| Diluted EPS | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 |
| Cash | |||||
| Cash from operations | $276M | $179M | $244M | $521M | $753M |
| Capital expenditure | $56.9M | $74.0M | $78.3M | $115M | $165M |
| Free cash flow | $219M | $104M | $165M | $405M | $589M |
| FCF margin | 22.9% | 10.2% | 10.5% | 16.1% | 20.0% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $145M | $226M | $85.8M | $301M |
| Share count change | 2.6% | −1.0% | 11.7% | 20.3% | −0.6% |
| Debt and strength | |||||
| Cash and short-term investments | $443M | $446M | $518M | $890M | $557M |
| Debt incl. finance leases | $0.0M | $0.0M | $418M | $444M | $0.8M |
| Shareholders' equity | $1.7B | $1.8B | $4.0B | $4.2B | $4.6B |
| Net debt / EBITDA | −1.8x | −1.5x | −0.4x | −1.1x | −0.7x |
| Current ratio | 6.2x | 6.2x | 4.9x | 2.5x | 4.3x |
| Returns and quality | |||||
| Return on capital | 12.0% | 13.2% | 3.7% | 3.7% | 11.0% |
| Return on equity | 9.2% | 10.6% | 4.2% | 2.5% | 12.3% |
| Piotroski F-score | 6 | 5 | 4 | 4 | 9 |
| Altman Z'' | 13.5 | 13.7 | 6.7 | 6.7 | 10.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$17.5M
7 insiders
Of sales under plans
39%
$6.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Globus Medical · GMED
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Globus Medical GMED | $11.2B | 16.7% | 16.3% | 20.0% | 11.0% | 21.0x | 9 |
| Revvity RVTY | $17.9B | 3.7% | 12.5% | 17.8% | 3.3% | 76.7x | 5 |
| Insulet PODD | $10.4B | 30.7% | 17.5% | 14.0% | 20.4% | 28.0x | 7 |
| AdaptHealth AHCO | $807M | −0.5% | 2.8% | 6.8% | 2.1% | — | 4 |
| Bruker BRKR | $8.9B | 2.1% | 2.0% | 1.3% | 0.9% | — | 4 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $81.83 a share, the company is worth $11.2B: 21.0 times its earnings of the last four quarters.
Globus Medical grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 0 of 2.
Source: SEC EDGAR XBRL filings (CIK 0001237831). Data updated October 14, 2026. For information only — not investment advice. Check the original filings before relying on any figure.